Protocol Ledger

NCT05237284 · Phase II · TERMINATED

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Interventional Phase II clinical trial protocol NCT05237284 sponsored by Sanofi in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-13 Enrollment: 305 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05237284
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)305 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05237284
Protocol FieldVerified Registry Value
NCT IdentifierNCT05237284
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment305 participants (ACTUAL)
Registered Start Date2022-04-13
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI